The new version of the new medical insurance drug catalog for full coverage of new coronary pneumonia drugs is launched today

The latest version of the National Medical Insurance Drug List was officially launched on March 1.

The “zombie drugs” were eliminated, new anti-cancer drugs, drugs related to the treatment of new coronary pneumonia, and the average price of newly included drugs were reduced by 50.

New coronary pneumonia medications are all included in medical insurance

Compared with previous years, one of the highlights of this medical insurance drug catalogue adjustment is that the number of drugs negotiated for price cuts is the largest and the treatment fields benefited the most.

Added 119 new medicines.

Newly added drugs related to the treatment of new coronary pneumonia.

17 new anti-cancer drugs have been added.

Call out 29 kinds of medicines.

New drugs "into the group".

It can be seen that the current medical insurance drug catalog adjustment includes cost-effective drugs, drugs with low clinical value, and full coverage of new coronary pneumonia-related drugs.

The average price of newly included drugs is reduced by 50.

This adjustment of the catalog is the first time to negotiate a price reduction for the "old varieties" in the catalog.

Compared with the drugs listed in the new access list, some "old products" have experienced price "upside-down" phenomenon.

Regarding the anti-cancer drugs in the catalog that expired at the end of 2020, the National Medical Insurance Bureau renewed or re-negotiations for 14 exclusive drugs according to the rules, with an average drop of 14.

Xiong Xianjun, director of the Medical Service Management Department of the National Medical Insurance Administration, said that under the premise that the medical insurance fund is generally safe and controllable, the medical insurance fund expenditure has not increased significantly, the drug expenditure of the insured patients has been significantly reduced, and the medical insurance drug protection capacity and level have been improved.

Multi-regional medical insurance drug catalog adjustment

With reference to the latest version of the medical insurance drug catalog, documents related to the implementation of the 2020 new version of the national drug catalog have been issued successively in many places across the country, as well as relevant notices of local supplementary drug catalogs.

  For example, the Beijing Medical Insurance Drug List has included all the newly added 119 drugs.
The reimbursement of drugs for special diseases in outpatient clinics has been adjusted and improved, and many new drugs have been included in outpatient special disease reimbursements.
For example, the new drugs "Sinimod" and "Fingolimod" have been included in the special outpatient department of "Multiple Sclerosis".
The scope of reimbursement for disease drugs, etc.
In addition, 19 other new drugs such as "Zebutinib" have been included in the scope of reimbursement of drugs for special diseases such as malignant tumors in Beijing.

  In addition to the unified classification management of negotiated drugs and high-value drugs, Sichuan Province has also included 12 negotiated drugs such as Degu aspartame and di-insulin in the scope of outpatient use of diabetes in the province's urban and rural residents.

  With the implementation of the new version of the medical insurance drug catalog, the National Medical Insurance Administration will also guide designated medical institutions to form linkages, optimize and upgrade the drugs equipped and used by institutions in a timely manner, improve the level of clinical drug use, and guide all regions to improve outpatient insurance policies and open medical insurance designated pharmacies channels , Reasonably adjust total control and other methods to promote the implementation of drugs in the new version of the catalog.